TrialBlood cancer journal2026

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Elias Jabbour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.